scholarly journals Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer

2013 ◽  
Vol 31 (6) ◽  
pp. 1587-1591 ◽  
Author(s):  
Cheryl Ho ◽  
Angela M. Davies ◽  
Randeep S. Sangha ◽  
Derick Lau ◽  
Primo Lara ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Phase I ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Solid Tumor ◽  
Small Cell ◽  
Advanced Solid Tumor ◽  
Small Cell Lung ◽  
Tumor Patients

scholarly journals Investigation of spleen CXCR4 expression by [68Ga]Pentixafor PET in a cohort of 145 solid cancer patients

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Richard Lewis ◽  
Stefan Habringer ◽  
Malte Kircher ◽  
Maike Hefter ◽  
Caroline Anna Peuker ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Solid Tumors ◽  
Neuroendocrine Tumors ◽  
Cell Lung Cancer ◽  
Solid Tumor ◽  
Small Cell ◽  
Cxcr4 Expression ◽  
Small Cell Lung ◽  
Tumor Patients

Abstract Background The chemokine receptor CXCR4 is frequently overexpressed and associated with adverse prognosis in most hematopoietic malignancies and solid cancers. Recently, CXCR4 molecular imaging using the CXCR4-specific positron emission tomography (PET) tracer Pentixafor ([68Ga]Pentixafor) has become a well-established method to non-invasively measure CXCR4 expression in vivo. In previous Pentixafor imaging studies, highly variable CXCR4 tracer uptake to the spleen was observed. Results We investigated the hypothesis that enhanced spleen [68Ga]Pentixafor uptake and thus CXCR4 expression in patients with solid tumors would indicate an activated spleen state and/or an association with clinical and prognostic features and survival parameters. In this retrospective study, [68Ga]Pentixafor-PET images and patient records of 145 solid tumor patients representing 27 cancer entities were investigated for an association of spleen [68Ga]Pentixafor uptake and clinical characteristics and outcome. Based on this assessment, we did not observe differences in clinical outcomes, measured by progression-free survival, overall survival and remission status neither within the entire cohort nor within subgroups of adrenal cancer, desmoplastic small round cell tumor, neuroendocrine tumors, non-small cell lung cancer, small cell lung cancer and pancreatic adenocarcinoma patients. No tumor entity showed especially high levels of spleen [68Ga]Pentixafor uptake compared to others or a control cohort. However, when investigating laboratory parameters, there was a positive correlation of high spleen [68Ga]Pentixafor uptake with leukocyte and/or platelet counts in neuroendocrine tumors, non-small cell lung cancer and small cell lung cancer. Conclusion Spleen [68Ga]Pentixafor uptake was not associated with stage of disease and clinical outcomes in solid tumor patients. We identified positively associated platelet and/or leukocyte counts with spleen [68Ga]Pentixafor uptake in neuroendocrine tumors, non-small cell lung cancer and small cell lung cancer, suggesting that splenic CXCR4 expression could possibly play a role in systemic immunity/inflammation in some types of solid tumors or a subgroup of patients within solid tumor entities.

A phase I study of novel dual Bcl-2/Bcl-xL inhibitor APG-1252 in patients with advanced small cell lung cancer (SCLC) or other solid tumor.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 2594-2594 ◽  
Author(s):  
Nehal J. Lakhani ◽  
Drew W. Rasco ◽  
Anthony W. Tolcher ◽  
Yingjie Huang ◽  
Jiao Ji ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Phase I ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Solid Tumor ◽  
Phase I Study ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer

2020 ◽  
Vol 25 ◽  
pp. 61-66
Author(s):  
Gerard M. Walls ◽  
Jamie B. Oughton ◽  
Anthony J. Chalmers ◽  
Sarah Brown ◽  
Fiona Collinson ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Phase I ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Novel Agents ◽  
Small Cell Lung ◽  
Conventional Radiotherapy

scholarly journals P2.03a-028 Phase I/II Trial of Carboplatin, nab-Paclitaxel and Bevacizumab for Advanced Non-Squamous Non-Small Cell Lung Cancer: Results of Phase I Part

2017 ◽  
Vol 12 (1) ◽  
pp. S905
Author(s):  
Satoshi Ikeo ◽  
Naoyuki Nogami ◽  
Hiromoto Kitajima ◽  
Hiroshige Yoshioka ◽  
Akihiro Bessho ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Phase I ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

Phase I Study of Weekly Alternating Therapy with Irinotecan/Cisplatin and Etoposide/Cisplatin for Patients with Small-Cell Lung Cancer

2003 ◽  
Vol 5 (1) ◽  
pp. 40-45 ◽  
Author(s):  
Faye M. Johnson ◽  
Jonathan M. Kurie ◽  
Beverly O. Peeples ◽  
J. Jack Lee ◽  
Lei Feng ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Phase I ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Phase I Study ◽  
Small Cell ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document